Jackson Creek Investment Advisors LLC Acquires 28,170 Shares of Collegium Pharmaceutical, Inc. $COLL

Jackson Creek Investment Advisors LLC grew its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 263.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 38,846 shares of the specialty pharmaceutical company’s stock after buying an additional 28,170 shares during the period. Jackson Creek Investment Advisors LLC’s holdings in Collegium Pharmaceutical were worth $1,799,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Versor Investments LP bought a new position in Collegium Pharmaceutical during the third quarter worth about $1,337,000. Ballast Asset Management LP boosted its position in Collegium Pharmaceutical by 31.1% during the third quarter. Ballast Asset Management LP now owns 114,315 shares of the specialty pharmaceutical company’s stock worth $4,000,000 after purchasing an additional 27,109 shares during the period. Wedge Capital Management L L P NC bought a new position in Collegium Pharmaceutical during the fourth quarter worth about $2,697,000. JPMorgan Chase & Co. boosted its position in Collegium Pharmaceutical by 193.8% during the third quarter. JPMorgan Chase & Co. now owns 211,757 shares of the specialty pharmaceutical company’s stock worth $7,409,000 after purchasing an additional 139,689 shares during the period. Finally, Hillsdale Investment Management Inc. boosted its position in Collegium Pharmaceutical by 14.1% during the third quarter. Hillsdale Investment Management Inc. now owns 203,000 shares of the specialty pharmaceutical company’s stock worth $7,103,000 after purchasing an additional 25,100 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Needham & Company LLC reissued a “buy” rating and issued a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. Finally, Truist Financial set a $58.00 price target on shares of Collegium Pharmaceutical in a report on Tuesday, February 10th. Four analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $57.50.

Collegium Pharmaceutical Trading Down 0.9%

Shares of Collegium Pharmaceutical stock opened at $33.78 on Wednesday. Collegium Pharmaceutical, Inc. has a 12-month low of $28.74 and a 12-month high of $50.79. The company has a market cap of $1.10 billion, a price-to-earnings ratio of 16.56 and a beta of 0.76. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. The company’s 50-day moving average price is $34.23 and its 200-day moving average price is $41.55.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm had revenue of $193.52 million for the quarter, compared to the consensus estimate of $184.47 million. During the same period in the prior year, the firm posted $1.49 earnings per share. The company’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, equities analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP David Dieter sold 13,976 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total value of $488,041.92. Following the sale, the executive vice president directly owned 77,071 shares of the company’s stock, valued at $2,691,319.32. This trade represents a 15.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Scott Dreyer sold 49,976 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the completion of the sale, the executive vice president directly owned 71,770 shares in the company, valued at $2,900,225.70. This represents a 41.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 1.85% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.